Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs (FUERTE)

November 17, 2026 updated by: Weill Medical College of Cornell University

Aim 3 Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs

The goal of this study is to learn whether FUERTE (Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs) can facilitate referrals of Hispanic men with prediabetes to the Diabetes Prevention Program (DPP) and support their continued engagement in the program.

The main questions it aims to answer are:

Does implementation of the FUERTE strategy increase the number of DPP-eligible Hispanic men who are referred to and enrolled in the DPP? Does implementation of the FUERTE strategy improve engagement in the DPP and result in greater improvements in weight and hemoglobin A1C among Hispanic men participating in the program?

FUERTE consists of three components:

  1. Information sessions for healthcare providers to increase awareness of the DPP.
  2. Text messages sent to DPP-eligible Hispanic men reminding them of appointments and encouraging discussions about prediabetes with healthcare providers.
  3. Interactive WhatsApp group messages for Hispanic men referred to the DPP, providing tailored content and discussion prompts related to each core DPP session.

Participants will:

  • Complete a survey before enrolling in the DPP.
  • Complete a survey after completing the DPP.
  • Those participating post-implementation of FUERTE will (1) receive text-messages, reminding them of their appointments and encouraging discussions about prediabetes with providers, and (2) receive interactive group-messages, delivered through WhatsApp, to supplement the standard of care DPP with tailored topics and prompts.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The goal of this single-site pilot implementation trial is to learn if FUERTE (Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs), a multi-component implementation strategy for Federally Qualified Health Centers, can feasibly facilitate referrals of Hispanic men with prediabetes to the Diabetes Prevention Program (DPP) and support their continued engagement in the program. FUERTE consists of 3 components: Component 1, information sessions to providers, to increase awareness of the DPP; Component 2, text-messages, delivered through existing appointment notification systems, sent to DPP-eligible Hispanic men, to remind them of their appointments and encourage discussions about prediabetes with providers; and Component 3, interactive group-messages, delivered through WhatsApp, to Hispanic men referred to the DPP, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP.

The main questions it aims to answer is whether:

Primary Hypothesis: FUERTE increases the proportion of DPP-eligible Hispanic men seen by a provider who are (1) referred to a Nutritionist for management of prediabetes, and (2) enrolled in a DPP.

Secondary Hypothesis: FUERTE increases (1) the proportion of providers referring DPP-eligible men for prediabetes management, and (2) the mean number of weeks Hispanic men attend the core component of the DPP.

Researchers will compare the results of participants seen by providers post-implementation of FUERTE with those seen pre-implementation of FUERTE.

Participants will:

Complete a survey before enrolling in the DPP, and after completing the program.

Those participating post-implementation of FUERTE will (1) receive text-messages, delivered through existing appointment notification systems, reminding them of their appointments and encouraging discussions about prediabetes with providers, and (2) receive interactive group-messages, delivered through WhatsApp, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New York
      • New York, New York, United States, 10065
        • Weill Cornell Medicine
        • Contact:
        • Principal Investigator:
          • Christopher J Gonzalez, MD MS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Self-reported Hispanic ethnicity and men
  • At least 18 years old
  • Have a body mass index (BMI) =>25 kg/m2
  • Have a documented HbA1c of 5.7%-6.4% within one year

Exclusion Criteria:

  • Life expectancy <12 months
  • not planning to stay in the geographic area for at least 6 months
  • diabetes based on an ICD-10 code in the previous 3 years
  • does not speak English or Spanish
  • present with a condition or abnormality (e.g., significant neurocognitive dysfunction) that in the opinion of the Investigator would compromise the ability of the patient to provide informed consent for the study activities, or the quality of the data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FUERTE Arm

Outside of this study, as part of their standard care, all participants will receive the Diabetes Prevention Program (DPP) and visits with the nutritionist at their site.

Participants in this arm of the study will complete a survey before enrolling in the DPP, and after completing the program. Participants will receive interactive group-messages, delivered through WhatsApp, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP.

Participants will complete a survey before enrolling in the Diabetes Prevention Program (DPP), and after completing the program. Participants will receive interactive group-messages, delivered through WhatsApp, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP.

Participants will complete a survey before enrolling in the Diabetes Prevention Program (DPP), and after completing the program.

Active Comparator: Standard Care

Outside of this study, as part of their standard care, all participants will receive the Diabetes Prevention Program (DPP) and visits with the nutritionist at their site.

Participants in this arm of the study will complete a survey before enrolling in the DPP, and after completing the program.

Participants will complete a survey before enrolling in the Diabetes Prevention Program (DPP), and after completing the program.

Other: Referring Providers

Referring Providers are assessed Pre and Post Implementation for the proportion of Providers seeing Diabetes Prevention Program (DPP) eligible men who then referred eligible men for Prediabetes Management.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The proportion of Diabetes Prevention Program-eligible Hispanic men seen by a provider and referred to a Nutritionist for management of prediabetes
Time Frame: 1 year
1 year
DPP Enrollment: The proportion of eligible Hispanic men enrolled in the Diabetes Prevention Program
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
Mean number of weeks attending the Core Component of the Diabetes Prevention Program, out of 16 possible
Time Frame: 6 months
6 months
Mean change in weight (kg) from baseline at 6 months
Time Frame: Baseline, 6 months
Baseline, 6 months
Mean change in A1C (%) from baseline at 6 months
Time Frame: Baseline, 6 months
Baseline, 6 months
Referring Providers: The proportion of Providers referring eligible Hispanic men to the Diabetes Prevention Program
Time Frame: 1 year
1 year
Referring Providers: The number of referrals placed by a Provider
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Christopher J Gonzalez, MD MS, Weill Medical College of Cornell University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

October 6, 2026

First Submitted That Met QC Criteria

October 12, 2026

First Posted (Actual)

October 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 26-06030420
  • K23DK139410-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All of the individual participant data collected during the trial, after deidentification.

IPD Sharing Time Frame

Immediately following publication. No end date.

IPD Sharing Access Criteria

Anyone who wishes to access the data.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.